AsiaOligonucleotide, Peptide
Shanghai Waigaoqiao, China
Discovery Synthesis for Oligonucleotide, Peptide & Conjugate Pre-formulation & Formulation Development for Oligonucleotides, Peptides & Conjugates
Site detail
Asia
Taixing, China
API Manufacturing for Oligonucleotides, Peptides & Conjugates
Please contact us for the full virtual tour.
API Manufacturing for Oligonucleotides, Peptides & Conjugates
- No.18 Tianxin Avenue, Taixing Economic Development Zone, Jiangsu China
The 169-acre site offers API manufacturing for oligonucleotides, peptides & conjugates at any scale.
When combining the peptide capacity in our Changzhou site, the total reactor volume of solid-phase peptide synthesizers at WuXi TIDES has reached over 41,000 L. To meet the growing customer needs, we plan to add more peptide manufacturing capacities soon.
In 2025, Taixing site successfully passed US FDA pre-approval inspection for an innovative peptide drug.
Site Virtual Tour
Site Related News
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shangh...
WuXi STA Starts Construction of New Site in Taixing China
On April 28, 2021, STA Pharmaceutical, a WuXi AppTec company, announced the construction of its Taixing site officially started. Located in Taixing Ec...
WuXi AppTec’s Changzhou and Taixing API Sites Successfully Pass FDA Inspections
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and m...
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shangh...
WuXi STA Starts Construction of New Site in Taixing China
On April 28, 2021, STA Pharmaceutical, a WuXi AppTec company, announced the construction of its Taixing site officially started. Located in Taixing Ec...
WuXi AppTec’s Changzhou and Taixing API Sites Successfully Pass FDA Inspections
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and m...
Nearby in the network
Other sites
AsiaOligonucleotide, Peptide
Changzhou, China
API Process Development and Manufacturing for Oligonucleotides, Peptides & Conjugates
Site detail
AsiaOligonucleotide, Peptide
Wuxi City, China
Pre-formulation, Formulation Development & Manufacturing for Oligonucleotides, Peptides & Conjugates
Site detail
How can we help?
Our TIDES drug experts stand ready.
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA